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Abstract
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenyan and Tanzanian
children aged 5 to 17 months. Here we report on the vaccine’s safety and tolerability. The experimental design was a Phase
2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study
or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were
collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days
after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14
months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety
monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total
of 894 children received RTS,S/AS01E or rabies vaccine between March and August 2007. Overall, children vaccinated with
RTS,S/AS01E had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01E
recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were
reported in 78% of subjects in the RTS,S/AS01E group and 74% of subjects in the rabies vaccine group. In both vaccine
groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently
observed solicited AE and was recorded after 11% of RTS,S/AS01E doses compared to 31% of doses of rabies vaccine. The
candidate vaccine RTS,S/AS01E showed an acceptable safety profile in children living in a malaria-endemic area in East
Africa. More data on the safety of RTS,S/AS01E will become available from the Phase 3 programme.
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Introduction
The most advanced malaria vaccine candidate currently under
evaluation is RTS,S/AS [1]. The RTS,S antigen construct has
been evaluated in combination with two different adjuvant
systems: AS01 and AS02. The ability of the vaccine to protect
against malaria has been demonstrated in studies involving North
American adults [2], African adults [3,4] and de-escalating age
groups in sub-Saharan Africa [5,6,7,8]. Previous studies have
evaluated the safety of RTS,S/AS in a range of populations from
varying locations and age groups [3,5,7,8,9,10,11,12,13,14,15,
16,17,18]. By the end of 2009, 1296 individuals had received 3720
doses of RTS,S/AS01 and 2826 individuals had received 7694
doses of RTS,S/AS02 in Phase 1 and 2 studies. To date, all
reports have suggested that RTS,S/AS is well tolerated and has a
good safety profile. Since preliminary data suggested better
immunogenicity with the AS01 adjuvant than AS02 [12,15], the
efficacy of the candidate RTS,S/AS01E against clinical malaria
was evaluated in a cohort of Kenyan and Tanzanian children 5 to
17 months of age. RTS,S/AS01E was found to have a protective
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efficacy of 53% (95% confidence interval [CI], 28% to 69%;
p,0.001) over an average follow-up period of 8 months [19]. Here
we report on the safety and tolerability of RTS,S/AS01E in
African children 5 to 17 months of age.
Methods
The study was registered at ClinicalTrials.gov (ClinicalTrials.gov
number: NCT00380393). Approval was obtained from the Kenyan
Medical Research Institute National Ethics Committee, the Tanza-
nian Medical Research Coordinating Committee, the Central
Oxford Research Ethics Committee, the London School of Hygiene
and Tropical Medicine Ethics Committee, and the Western
Institutional Review Board in Seattle. The study was overseen by
an Independent data monitoring committee and local safety
monitors, and conducted in accordance with the Helsinki Declaration
of 1964 (revised 1996) and Good Clinical Practice guidelines. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1.
Study sites
The study was conducted at two study sites: Korogwe district,
Tanzania and Kilifi district, Kenya. Both sites are within 100km of
the coast of the Indian Ocean and within 300 km of each other.
The study sites have been previously described [19]. Briefly, in
Kilifi, Kenya, children were recruited in two administrative
locations (Pingilikani and Junju), within the Chonyi area in the
southern part of Kilifi District. In Tanzania, children were
recruited from the catchment areas of three dispensaries
(Ngombezi, Mbagai and Makuyuni) in Korogwe district, Tanga
Region. Both sites are malaria endemic, with all year round
transmission and two high transmission seasons. There are
successful ITN distribution programmes in both countries and
artemether/lumefantrine was the first line anti-malarial treatment.
There were no insecticide spraying campaigns in the area at the
time of the study. Both areas are rural, and most of the population
are subsistence farmers.
The participants, who were residents of the study area, were
healthy male and female children aged 5 to 17 months at the time of
the first vaccination. All children had been previously vaccinated with
HBs as part of the Expanded Programme on Immunisation (EPI).
Sensitisation and informed consent
To obtain informed consent a multistage sensitisation process
was undertaken. In both sites the planned trial was first discussed
with the village elders. After the elders granted permission public
meetings were held during which the trial was explained to all
interested villagers. Following the meetings the parents of eligible
children were visited by study staff familiar with the village to
answer specific questions regarding the participation in the trial.
There were subtle differences in conduct of the sensitisation
between the two sites which have been described by Lang and
coworkers [20]. Following the sensitisation consenting parents
were asked to sign a written informed consent using approved
Swahili or Giriama consent forms. The thumb print of an illiterate
parents on the consent form, countersigned by an independent,
literate witness was accepted.
Study Design
The experimental design was a Phase 2b, randomised (1:1 ratio)
controlled trial. The blinding of study staff and participants
differed during the first and the second phase of the trial and is
illustrated in Figure 1. The mean duration study children
participated in the first phase was 10 months (range: min 7.1;
max 12.8 months post-dose 1; SD 1.3). During the first phase of
the trial study staff and parents/guardians of participating children
were blinded after which the investigators were unblinded but the
parents/guardians of participating children remained blinded
Figure 1. Study design overview. BS; Blood Sample, Vacc; Vaccination, Extension; Extension of the single-blind Phase. XsecDB: cross sectional
at the end of double-blind Phase (; mean follow-up: 10 months, range: min 7.1; max 12.8 months post-dose 1; SD 1.3). XsecExt: cross sectional at the
end of the extension Phase; mean follow-up: 18 months (range: min 13.8; max 20.1 months post-dose 1; SD 1.5). *Clinic Visit 8 took place on the same
day as clinic Visit 7 and included consent process for participation in the extension Phase (Kilifi only). **Applicable to Kilifi only.
doi:10.1371/journal.pone.0014090.g001
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(Figure 1). In Korogwe, participating children were followed until
study conclusion 14 months after dose 1. In Kilifi, children
participated in an extended follow-up until the end of the
transmission period in October 2008, for all subjects regardless
of their enrolment date. This design resulted in different post-
vaccination times for individual subjects. The average follow-up
period for these subjects was 18 months post-dose 1 in Kenya
(range: min 13.8; max 20.1 months post-dose 1; SD 1.5).
Vaccines
All subjects were randomised to receive either RTS,S/AS01E
(GlaxoSmithKline [GSK] Biologicals, Belgium) or a rabies
vaccine. RTS,S is composed of two polypeptides which are co-
expressed in Saccharomyces cerevisiae. One polypeptide RTS includes
fractions of the Plasmodium falciparum circumsporozoite protein,
specifically the CSP repeat region (R), T-cell epitopes (T) fused to
‘‘S’’, the hepatitis B virus surface antigen (HbsAg) [21]. The other
polypeptide, the second S, includes the unfused HbsAg sequence.
The two polypeptides assemble spontaneously to form virus like
particles. The antigen RTS,S is administered in the proprietary
Adjuvant System AS01 comprising liposomes, MPL (3-D-deacy-
lated Monophosphoryl Lipid A) and QS21 (a triterpene glycoside
purified from the bark of Quillaja saponaria) [21]. The suffix ‘‘E’’
indicates the paediatric dose formulation of AS01, which is the
only dose used throughout this trial. The control was a human
diploid-cell rabies vaccine (Sanofi-Pasteur). AS01E is presented in
a 3 mL monodose vial. One dose contains 25 ug of MPL and
25 ug of StimulonH QS21 (a triterpene glycoside purified from the
bark of Quillaja saponaria) with liposomes. The potency of one
dose (1.0 mL) of Sanofi-Pasteur’s Human Diploid Cell Rabies
Vaccine is at least 2.5 IU of rabies antigen. Sanofi-Pasteur’s
Human Diploid Cell Rabies Vaccine is a creamy white to orange,
freeze-dried vaccine for reconstitution with the diluent prior to
use; the reconstituted vaccine is a clear to slightly opaque,
colourless suspension.
Enrolment and vaccinations
Children between 5 months and 17 months of age at the time of
first vaccination, who were judged at the time of assessment to
have no serious acute or chronic illness as determined by clinical
or physical examination, medical history records or laboratory
screening tests, were eligible to participate in the trial, provided
that the parents or guardians gave their consent. Re-consent was
obtained from parents or guardians of subjects for participation in
the extension follow-up in Kilifi. Vaccines were administered
intramuscularly into the left deltoid at 0, 1, and 2 months. The
screening and vaccinations were conducted in clinics which were
built or rehabilitated for the purpose of this trial as existing clinic
space was in high demand. The RTS,S/AS01E and rabies
vaccines were packaged in identical boxes labelled with treatment
numbers from a randomization list generated at GSK, and then
shipped to the trial sites. Block randomization was used (Block
size = 6), with stratification according to study site. Subjects were
assigned treatment numbers on the basis of order of attendance at
the clinic. Blinding was maintained using a range of measures
including opening labelled boxes out of sight of the investigators
who evaluated the study end points, study subjects and their
parents or guardians, masking syringes and vaccine preparation
being undertaken by personnel who took no other part in study-
related procedures.
Definitions
An adverse event (AE) was defined as any untoward medical
occurrence in a study participant whether or not considered
related to the vaccine. A serious adverse event (SAE) was defined
as any untoward medical occurrence that resulted either in death,
was life-threatening, required hospitalization or prolongation of
existing hospitalization, resulted in disability or was considered
severe by the investigators. SAEs were classified according to the
preferred term in the Medical Dictionary for Regulatory Activities
(MedDRA) [22]. The intensity of all AEs was graded from 1 to 3,
with 3 being the most severe (Table 1). For seizures occurring
within 7 days of vaccination, data collection and presentation was
undertaken according to the Brighton Collaboration guidelines.22
Adverse events were treated according to standard medical
practice and followed up until resolution. For all general solicited
AEs and all unsolicited serious and non-serious AEs the
investigators’ assessment of causal relationship to vaccination
was recorded: ‘yes’, there was a reasonable possibility that the
vaccination contributed to the event, or ‘no’, the vaccination was
not suspected to have contributed to the AE; there are other more
likely causes. Abnormal assessments from interview, examination
or laboratory results that were judged by the investigator to be
clinically significant were recorded as AEs or SAEs. Severe malaria
was defined prospectively according to standard case definitions
(Table 2), and confirmed by medical review of patient records.
Solicited AEs
Solicited AEs were recorded for 7 days after each vaccination
[vaccination Day 0 (at the clinic) and for the 6 subsequent days].
Trained field workers visited each child at home, daily on days 1
through 6 following each vaccination and completed a structured
interview regarding local and general AEs. Local solicited AEs
included pain at the injection site (defined as a participant’s
reaction to touch or movement of the injected site or arm),
swelling at the injection site (defined as enlargement or bulging).
General solicited adverse events included fever (defined as an
axillary temperature $37.5uC), irritability or fussiness (defined as
abnormal crying), drowsiness (defined as sleepiness or tiredness),
loss of appetite (defined as eating less than usual). If a field worker
found any Grade 3 symptom, the participant was examined by a
study physician.
Unsolicited AEs
Non-serious unsolicited AEs were monitored for 30 days after
each vaccination. Events were mainly captured when a child
presented unwell to a health facility in the study area where a
surveillance system was implemented. The child was reviewed by
clinically qualified personnel and treated as required. In addition
symptoms identified by field workers at scheduled visits (solicited
AE data collection or at a 2-weekly home visit [starting 14 days
post-dose 3 and continuing until study end]) were reported to
medical research staff, who evaluated the symptom and arranged
clinical reviews as appropriate.
SAEs
SAEs were documented from the administration of the first
vaccine dose until the study conclusion at 14 months post-dose 1 in
Korogwe and an average of 18 months post-dose 1 in Kilifi. A
study physician reviewed medical details of all SAEs before
unblinding at the end of both the double-blind phase and the study
prior to data analysis (Figure 1). In the case of a death,
supplementary information was collected using a verbal autopsy.
Laboratory tests
Blood samples for safety monitoring of haematological (haemo-
globin, white cell count, platelet count), renal (creatinine) and
Mal-49 Safety Paper
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Table 1. Intensity scales for adverse events following vaccination.
Adverse Event Intensity grade Parameter
Pain at injection site 0 Absent
1 Minor reaction to touch
2 Cries/protests on touch
3 Cries when limb is moved/spontaneously painful
Swelling at injection site 0 None
1 ,5 mm
2 5 to 20 mm
3 .20 mm
Fever* 0 ,37.5uC
1 37.5–38.0uC
2 .38–39.0uC
3 .39.0uC
Irritability or Fussiness 0 Behaviour as usual
1 Crying more than usual/no effect on normal activity
2 Crying more than usual/interferes with normal activity
3 Crying that cannot be comforted/prevents normal activity
Drowsiness 0 Behaviour as usual
1 Drowsiness easily tolerated
2 Drowsiness that interferes with normal activity
3 Drowsiness that prevents normal activity
Loss of appetite 0 Appetite as usual
1 Eating less than usual/no effect on normal activity
2 Eating less than usual/interferes with normal activity
3 Not eating at all
*Fever is defined as axillary temperature $37.5uC.
doi:10.1371/journal.pone.0014090.t001
Table 2. Severe malaria definitions for reporting of SAEs.
Severe malaria anaemia Asexual P. falciparum parasitemia .0 definitive reading
Hematocrit ,15%1
No other more probable cause of illness
Cerebral malaria Asexual P. falciparum parasitemia .0 definitive reading
Coma score #22
No other identifiable cause of loss of consciousness
Severe malaria (other) Asexual P. falciparum parasitemia .0 definitive reading
No other more probable cause of illness
Does not meet criteria for severe malaria anaemia or cerebral malaria
One of the following:
Multiple seizures3
Prostration4
Hypoglycemia5
Acidosis
Circulatory collapse
1The lowest value recorded by either centrifuge or Coulter counter at any point during the admission was used to determine a case.
2The coma-score was assessed after correction of hypoglycemia and 60 minutes after control of fits. If fitting could not be controlled within 30 minutes the child was
diagnosed with cerebral malaria.
3Two or more generalized convulsions within a 24-hour period prior to admission.
4Inability to sit unaided.
5,2.2 mmol/dL.
doi:10.1371/journal.pone.0014090.t002
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hepatic function (alanine transferase) were collected four times
during the study period: at baseline; 3 months post-dose 1, at the
end of the double-blind phase (mean 10.1 months, SD 1.3) and 14
months post-dose 1. The severity of abnormal laboratory results
was graded (Table 3). When a temperature $37.5uC was
recorded, a blood film was made and a rapid test (OptimalH) for
malaria was conducted. Rapid test results were used to make
treatment decisions, but the blood film results (read in duplicate)
were used to define the protocol-defined study endpoint, presence
or absence of malaria. In Korogwe, biochemical parameters were
measured using a dry biochemistry photometer VITROS DT
Control II (Orto Clinical Diagnostics, Johnson & Johnson
Company, NY, USA). Haematological tests were undertaken
using a Sysmex KX-21N cell counter (Sysmex Corporation Kobe,
Japan). In Kilifi, biochemical parameters were measured using a
Selectra E analyzer (Vital Scientific, The Netherlands) and
haematological tests were undertaken using a Coulter Counter
AcT 5Diff CP (Beckmann Coulter, Florida, USA). In addition, in
Kilifi a microbiology laboratory was available to isolate and
identify bacterial pathogens. The study protocol did not require
testing for the presence of HIV infection for inclusion. No child
was diagnosed with HIV infection during the conduct of the
trial.
Analysis
The safety analysis was performed on the total vaccinated
cohort. AEs and SAEs, as well as laboratory results at baseline and
post-vaccination, were tabulated according to vaccine group
attribution with exact 95% Confidence Intervals (CI). Biochemical
and haematological parameters outside the normal range were
described; the frequency distribution of results by toxicity grades
(Table 3) was tabulated by group. SAS version 8 (SAS, Cary, NC,
USA) was used for the data analysis.
Results
Vaccinations took place over a 6-month period from March
until August 2007. The disposition of study participants is shown
in Figure 2. A total of 894 subjects received the first dose of either
RTS,S/AS01E (N=447) or the rabies vaccine (N= 447). The
mean age of children was 11.4 months (SD 3.6) in the RTS,S/
AS01E group and 11.4 months (SD 3.4) in the rabies group. 229
subjects who received RTS,S/AS01E (51%) and 222 children who
received the rabies vaccine (50%) were girls. Fourteen months
after receiving the first dose, 57 children in the RTS,S/AS01E
group (13%) and 56 children in the rabies vaccine group (13%)
were lost to follow-up. Of the 447 children enrolled in Kilifi, 349
(78%) participated in the extension follow-up and 327 (73%)
completed the last study visit.
We compared the occurrence of solicited local and general AEs
within 7 days following each dose and overall (Table 4). Fever was
the most frequently observed solicited AE and occurred more
frequently after the rabies vaccine (409 of 1318 vaccinations, 31%)
than after RTS,S/AS01E (149 of 1320; 11%) (Table 4). All febrile
convulsions occurred within the 7 day follow-up period. The
second most common solicited AE was pain. Low grade pain (1–2
intensity grade) was recorded after 13% of the RTS,S/AS01E
vaccinations (172 of 1320) and 12% of the rabies vaccinations (157
of 1318). No pain with grade 3 intensity was reported. Irritability
was recorded following 59 (5%) of 1320 RTS,S/AS01E admin-
istrations and following 21 (2%) of 1318 rabies vaccine
administrations. Swelling at the vaccination site, drowsiness, and
loss of appetite were infrequently observed and similarly
distributed among RTS,S/AS01E and rabies vaccine recipients.
Unsolicited AEs were equally balanced between both study groups
(Table S1). Unsolicited AEs were reported in 78% of subjects in
the RTS,S/AS01E group and 74% of subjects in the rabies vaccine
group. In both vaccine groups, gastroenteritis and pneumonia
were the most frequently reported unsolicited AE19.
Table 5 presents details of SAE following administration of
RTS,S/AS01E and the rabies vaccine. Overall, SAEs occurred
more frequently in children in the control group than in the
RTS,S/AS01E group: 88/447 children who received the rabies
vaccine (20%; 95% CI 16% to 24%) compared to 51/447 children
who received RTS,S/AS01E (11%; 95% CI 9% to 15%) had at
least one SAE. One SAE episode in a RTS,S/AS01E recipient and
nine episodes among eight rabies vaccine recipients met the
criteria for severe malaria described (Table 2). Three children in
the control group had cerebral malaria and one had severe
anaemia. All children treated for severe malaria recovered without
sequelae. The most frequently detected SAEs in both groups were
pneumonia (n = 42), febrile convulsions (n = 34), P. falciparum
infection (n= 33), gastroenteritis (n = 32), and upper respiratory
tract infections (n = 12). One SAE, a febrile convulsion in a subject
from the RTS,S/AS01E group, was considered by the investigator
to be causally related to the study vaccine. The child was closely
followed and had no sequelae. Two deaths, both following
convulsions, were reported. In the RTS,S/AS01E group, a 17-
month-old boy died at home 9 months after the third dose of
RTS,S/AS01E. A 2-year-old boy died 13 months after the third
dose of rabies vaccine. The verbal autopsies conducted after the
deaths failed to ascertain the aetiologies for either death. Both fatal
SAEs were considered by investigators to be unrelated to study
vaccination.
Table 3. Grading scale for laboratory results following vaccination.
Acceptable limit/normal range Toxicity grade
1 2 3 4
Haemoglobin $8.0 g/dL ,8.0 g/dL ,6.0 g/dL ,5.0 g/dL ,5.0 g/dL & clinical signs
Total white cell count{ $4.06103/mL to ,176103/mL 2.5 to 4.06103/mL 1.5 to 2.46103/mL 1.0 to 1.46103/mL ,1.06103/mL
Platelets{ $756103/mL 50 to 746103/mL 25 to 496103/mL ,256103/mL ,256103/mL & clinical signs
ALT* #60 IU/L 1.1 to 2.56ULN** 2.6 to 5.06ULN 5.1 to 10.06ULN .10.06ULN
Creatinine* #60 mmol/L 1.1 to 1.56ULN 1.6 to 3.06ULN 3.1 to 6.06ULN .6.06ULN or requires dialysis
{Grading scale adapted from Division of AIDS table for grading severity of adult and paediatric adverse events December 2004.
*Grading scale adapted from WHO Toxicity Grading Scale for Determining Severity of Adverse Events, February 2003.
**ULN: Upper Limit of Normal.
doi:10.1371/journal.pone.0014090.t003
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The most frequently observed haematological abnormality was
anaemia which was observed in ,2% RTS,S/AS01E and ,4%
rabies vaccine recipients during the 3 post-vaccination blood
draws and in similar proportions in both groups overall (Table 6).
Abnormal white cell counts and platelet counts were detected in
1% or fewer study participants and in a similar proportion in both
vaccine groups. At 14 months post-dose 1, an elevated ALT was
recorded in samples from 14 children in the RTS,S/AS01E group
and from 16 children in the control group. An elevated creatinine
was detected in ,1% of study participants and in similar
proportions in each vaccine group.
Discussion
In this study involving children aged 5 to 17 months, living in a
malaria-endemic area, a three-dose regimen of RTS,S/AS01E was
well tolerated. Fever within 7 days of vaccination occurred less
frequently following RTS,S/AS01E (after 11% of doses) than after
Figure 2. The assembly and disposition of study participants. a Subjects were temporally out of study area but returned for Month 14 (M14)
visit. b Investigator decided not to continue vaccination as EPI vaccination documentation was not available, this subject returned for Month 14 (M14)
visit. c One subject died after consent withdrawal.
doi:10.1371/journal.pone.0014090.g002
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rabies vaccination (31%). Whilst this occurrence is comparable
with some studies9,14, it is lower than other trials, in which an
incidence up to 48% has been observed5,23. Fever could be a
factor for vaccine acceptability and adherence to the three dose
vaccine schedule. Parents or guardians may be reluctant to
vaccinate their child if fever occurred after vaccinations. In our
study febrile convulsions were recorded in 3.1% of the RTS,S/
AS01E and 4.5% of the control subjects. A single episode of febrile
convulsions following a dose of RTS,S/AS01E was considered to
be causally related to the study vaccine. A similar case has been
previously reported23. Post-vaccination febrile seizures are well
described, hence the occurrence of febrile seizures will have to be
Table 4. Frequency (%) of solicited local and general adverse events within 7 days following each dose and overall.
RTSS/AS01E Rabies
Symptom/Sign Dose Intensity Grade N n % 95% CI N n % 95% CI
Pain Dose 1 Any 447 51 11.4 8.6 14.7 447 39 8.7 6.3 11.7
Dose 2 Any 439 45 10.3 7.6 13.5 438 38 8.7 6.2 11.7
Dose 3 Any 434 76 17.5 14.1 21.4 433 80 18.5 14.9 22.5
Overall Any 1320 172 13.0 11.3 15.0 1318 157 11.9 10.2 13.8
Swelling Dose 1 Any 447 20 4.5 2.8 6.8 447 12 2.7 1.4 4.6
Dose 2 Any 439 6 1.4 0.5 3.0 438 3 0.7 0.1 2.0
Grade 3 439 1 0.2 0.0 1.3 438 0 0.0 0.0 0.8
Dose 3 Any 434 8 1.8 0.8 3.6 433 1 0.2 0.0 1.3
Grade 3 434 2 0.5 0.1 1.7 433 0 0.0 0.0 0.8
Overall Any 1320 34 2.6 1.8 3.6 1318 16 1.2 0.7 2.0
Grade 3 1320 3 0.2 0.0 0.7 1318 0 0.0 0.0 0.3
Drowsiness Dose 1 Any 447 44 9.8 7.2 13.0 447 28 6.3 4.2 8.9
Dose 2 Any 439 22 5.0 3.2 7.5 438 25 5.7 3.7 8.3
Grade 3 439 0 0.0 0.0 0.8 438 1 0.2 0.0 1.3
Dose 3 Any 434 15 3.5 1.9 5.6 433 11 2.5 1.3 4.5
Overall Any 1320 81 6.1 4.9 7.6 1318 64 4.9 3.8 6.2
Grade 3 1320 0 0.0 0.0 0.3 1318 1 0.1 0.0 0.4
Fever Dose 1 Any 447 55 12.3 9.4 15.7 447 138 30.9 26.6 35.4
Grade 3 447 1 0.2 0.0 1.2 447 2 0.4 0.1 1.6
Dose 2 Any 439 56 12.8 9.8 16.2 438 159 36.3 31.8 41.0
Grade 3 439 3 0.7 0.1 2.0 438 8 1.8 0.8 3.6
Dose 3 Any 434 38 8.8 6.3 11.8 433 112 25.9 21.8 30.3
Grade 3 434 1 0.2 0.0 1.3 433 2 0.5 0.1 1.7
Overall Any 1320 149 11.3 9.6 13.1 1318 409 31.0 28.5 33.6
Grade 3 1320 5 0.4 0.1 0.9 1318 12 0.9 0.5 1.6
Irritability Dose 1 Any 447 26 5.8 3.8 8.4 447 12 2.7 1.4 4.6
Dose 2 Any 439 16 3.6 2.1 5.9 438 7 1.6 0.6 3.3
Dose 3 Any 434 17 3.9 2.3 6.2 433 2 0.5 0.1 1.7
Overall Any 1320 59 4.5 3.4 5.7 1318 21 1.6 1.0 2.4
Loss of appetite Dose 1 Any 447 34 7.6 5.3 10.5 447 28 6.3 4.2 8.9
Grade 3 447 0 0.0 0.0 0.8 447 1 0.2 0.0 1.2
Dose 2 Any 439 24 5.5 3.5 8.0 438 13 3.0 1.6 5.0
Grade 3 439 0 0.0 0.0 0.8 438 1 0.2 0.0 1.3
Dose 3 Any 434 6 1.4 0.5 3.0 433 2 0.5 0.1 1.7
Overall Any 1320 64 4.8 3.8 6.1 1318 43 3.3 2.4 4.4
Grade 3 1320 0 0.0 0.0 0.3 1318 2 0.2 0.0 0.5
For each dose:
N = number of subjects with at least one administered dose.
n (%) = number of doses followed by the symptom/sign.
For Overall/dose:
N = number of administered doses.
n(%) = number(percentage) of doses followed by at least one type of symptom.
95%CI = Exact 95% confidence interval.
The absence of a grade in the table suggests that none of the participants was included in this grade.
doi:10.1371/journal.pone.0014090.t004
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closely monitored in future RTS,S/AS01E trials. Other signs of
vaccine reactogenicity including pain, swelling, drowsiness,
irritability and loss of appetite tended to be mild and infrequent.
Interestingly, children vaccinated with RTS,S/AS01E had
significantly fewer SAEs than children in the control group. In
particular, children who had received RTS,S/AS01E recorded less
pneumonia or gastroenteritis during the 14-months post-vaccina-
tion surveillance period. One potential explanation for this finding
is that children who were protected against malaria may have been
indirectly protected against other infectious diseases due to overall
better health and a less severely and frequently challenged
immune system. The implication of this explanation would be a
considerable improvement in the health of children living in
malaria endemic areas once a protective malaria vaccine becomes
universally available24.
An important limitation of our trial was that as only 447
children received the RTS,S/AS01E vaccine, the study was not
powered to detect a rare event. Considering the very large target
population for a malaria vaccine, more data on the safety of
RTS,S/AS01E will be needed before licensure and roll-out. A
large, multicentre Phase 3 trial of RTS,S/AS01E in which up to
16,000 children will participate is currently under way and will
greatly extend the safety database.
Supporting Information
Table S1 Unsolicited events tables.
Found at: doi:10.1371/journal.pone.0014090.s001 (0.20 MB
DOC)
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0014090.s002 (0.22 MB
DOC)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0014090.s003 (1.40 MB
PDF)
Table 5. Serious Adverse Events (The number of severe
malaria cases have been previously been described [19]. One
child in the RTS,S/AS01E and 9 children in the rabies vaccine
arm were diagnosed with severe malaria.)
RTS,S/AS01E
N=447
Rabies
N=447
n % 95% CI n % 95% CI
At least one SAE 51 11.4 8.6 14.7 88 19.7 16.1 23.7
At least one SAE excluding
malaria related SAEs
50 11.2 8.4 14.5 85 19.0 15.5 23.0
SAEs occurring in more
than one subject
Pneumonia 16 3.6 2.1 5.7 26 5.8 3.8 8.4
Febrile convulsion 14 3.1 1.7 5.2 20 4.5 2.8 6.8
Gastroenteritis 10 2.2 1.1 4.1 22 4.9 3.1 7.4
Plasmodium falciparum
infection
8 1.8 0.8 3.5 25 5.6 3.7 8.1
Upper respiratory tract
infection
8 1.8 0.8 3.5 4 0.9 0.2 2.3
Anaemia 5 1.1 0.4 2.6 11 2.5 1.2 4.4
Urinary tract infection 3 0.7 0.1 1.9 0 0.0 0.0 0.8
Convulsion 3 0.7 0.1 1.9 2 0.4 0.1 1.6
Dysentery 2 0.4 0.1 1.6 1 0.2 0.0 1.2
Asthma 2 0.4 0.1 1.6 1 0.2 0.0 1.2
Bronchiolitis 1 0.2 0.0 1.2 3 0.7 0.1 1.9
Cholera 1 0.2 0.0 1.2 2 0.4 0.1 1.6
Malnutrition 1 0.2 0.0 1.2 2 0.4 0.1 1.6
Rectal prolapse 0 0.0 0.0 0.8 2 0.4 0.1 1.6
Cerebral malaria 0 0.0 0.0 0.8 3 0.7 0.1 1.9
Petroleum distillate
poisoning
0 0.0 0.0 0.8 2 0.4 0.1 1.6
Thermal burn 0 0.0 0.0 0.8 2 0.4 0.1 1.6
Marasmus 0 0.0 0.0 0.8 2 0.4 0.1 1.6
Bronchial hyperreactivity 0 0.0 0.0 0.8 2 0.4 0.1 1.6
N= number of subjects with at least one administered dose.
n/%=number/percentage of subjects reporting at least once the symptom.
95% CI = exact 95% confidence interval.
doi:10.1371/journal.pone.0014090.t005
Table 6. Frequency (%) of abnormal laboratory results
following vaccination.
Toxicity
grade RTS,S/AS01E Rabies vaccine
N=447 N=447
n (%) n (%)
Haemoglobin
month 3 1 7 (1.7) 10 (2.4)
month 9 1 6 (1.5) 8 (2.0)
month 14 1 5 (1.3) 14 (3.6)
2 1 (0.3) 0 (0.0)
White blood cells
month 3 1 0 (0.0) 1 (0.2)
month 14 1 0 (0.0) 1 (0.3)
Platelets
month 3 1 1 (0.2) 0 (0.0)
2 2 (0.5) 4 (0.9)
3 0 (0.0) 1 (0.2)
month 9 1 4 (1.0) 1 (0.3)
2 1 (0.3) 0 (0.0)
month 14 1 1 (0.3) 1 (0.3)
2 2 (0.5) 4 (1.0)
3 1 (0.3) 3 (0.8)
Alanine transferase
month 3 1 1 (0.2) 2 (0.5)
2 0 (0.0) 1 (0.2)
month 9 1 5 (1.3) 8 (2.0)
2 0 (0.0) 1 (0.2)
month 14 1 11 (2.8) 13 (3.4)
2 2 (0.5) 2 (0.5)
3 1 (0.3) 0 (0.0)
4 0 (0.0) 1 (0.3)
Creatinine
month 9 1 1 (0.3) 0 (0.0)
2 0 (0.0) 1 (0.2)
month 14 1 0 (0.0) 2 (0.5)
doi:10.1371/journal.pone.0014090.t006
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